TMC435350

DRUG3 trials

Sponsors

Tibotec Pharmaceuticals, Ireland

Conditions

HCVHepatitis CPharmacokineticsRifampinTuberculosis

Phase 1

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

CompletedNCT00741169

Tibotec Pharmaceuticals, IrelandHCV, Hepatitis C, Pharmacokinetics +2

Start: 2008-06-30End: 2008-12-31Updated: 2013-04-18

TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule

CompletedNCT00752648

Tibotec Pharmaceuticals, IrelandHCV, Hepatitis C

Start: 2008-07-31End: 2009-01-31Updated: 2010-04-28

TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers

CompletedNCT00752544

Tibotec Pharmaceuticals, IrelandHCV

Start: 2008-08-31End: 2008-11-30Updated: 2010-04-28

Related Papers

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.

2013-09-0560 citations